 RESEARCH TRIANGLE PARK, N.C., May 19, 2021 GLOBE NEWSWIRE -- G1 Therapeutics, Inc. Nasdaq: GTHX, a commercial-stage oncology company, today announced upcoming data presentations at the American Society of Clinical Oncology ASCO annual meeting, being held virtually June 4th through 8th. The presentations will describe results from the Companys study of its oral selective estrogen receptor degrader SERD, rintodestrant, in combination with palbociclib for the treatment of ERHER2- advanced breast cancer as well as data describing the effects of COSELATM trilaciclib on T-cell activation and clonal expansion in patients with newly diagnosed extensive-stage small cell lung cancer. A copy of the posters will be made available on the G1 corporate website on June 4, 2021. 